Next generation genetic sequencing (NGS) will have a profound effect on the healthcare landscape. Within the foreseeable future, NGS will be cost-effectively and readily available to large patient groups - we can even envisage most citizens having their exome sequenced in post natal screening programmes. Grünfeld, a former McKinsey consultant, M.D. and molecular geneticist, is better placed than most to analyse its impact, as Norway is one of few countries which is piloting a nationwide programme to deploy NGS technologies to widespread clinical practice. What will such platforms look like, who will do the work and what impact will it have? Thomas looks specifically at the impact on private diagnostic labs and healthcare providers. Presented at the Healthcare Europa Annual Conference 2014, The Return of the Bull Market.